Chronic obstructive pulmonary disease (COPD) interferes with normal breathing and may result in shortness of breath (dyspnea), wheezing, chest tightness and a productive cough.
The AIRFLOW-2 Clinical Trial uses a catheter-based system called the Nuvaira™ Lung Denervation System to address chronic obstructive pulmonary disease (COPD).
Targeted Lung Denervation (TLD) is a one-time non-surgical procedure that may improve control of COPD symptoms.
This post is also available in:
French German Dutch